Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 13/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26352330 | 0.91 | MAPT (0.45) | IRAK4MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL19030464 | 0.89 | ALDH1A1 (0.47) | IRAK4MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL19030443 | 0.88 | IRAK4 (0.51) | IRAK4MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL19030560 | 0.88 | IRAK4 (0.50) | IRAK4MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL19030431 | 0.85 | IRAK4 (0.50) | IRAK4MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL19030128 | 0.82 | IRAK4 (0.52) | IRAK4 | |
| SCHEMBL19030454 | 0.82 | AKR1B1 (0.46) | IRAK4MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL19030153 | 0.82 | MAPT (0.46) | IRAK4MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL19030693 | 0.81 | IRAK4 (0.48) | IRAK4MAPTALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL19029918 | 0.81 | MAPT (0.46) | MAPTALDH1A1CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2022-10-20 | — | — | US | disclosed |
| CN-114502158-A | IRAK degradation agent and application thereof | 凯麦拉医疗公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3989966-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-108473498-B | Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-3394066-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | H. Hoffnabb-La Roche Ag (CH) | 2018-10-31 | — | — | EP | disclosed |
| US-20180298015-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2018-10-18 | — | — | US | disclosed |
| WO-2017108723-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | disclosed |
| WO-2017108723-A2 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | IRAK4 3/4885MAPT 3470/4885ALDH1A1 4348/4885 |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK4 | IRAK4 3/4885MAPT 4151/4885ALDH1A1 3721/4885 |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885MAPT 2459/4885ALDH1A1 2776/4885 |
| US-20230069104-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK4, IRAK2, IRAK3 | IRAK4 1/4885MAPT 1491/4885ALDH1A1 3918/4885 |
| US-20180298015-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885MAPT 1916/4885ALDH1A1 1146/4885 |
| US-20220332718-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885MAPT 2319/4885ALDH1A1 1115/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | IRAK4 4/4885MAPT 2459/4885ALDH1A1 2776/4885 |
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885MAPT 1916/4885ALDH1A1 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.